Mehak Sandhu
Independent Researcher
Punjab, India
Abstract
Moderate-to-severe plaque psoriasis is a chronic, immune-mediated inflammatory skin condition characterized by well-demarcated erythematous plaques. Biologic therapies targeting specific inflammatory pathways have revolutionized psoriasis management. Guselkumab (Tremfaya) and Tildrakizumab, both IL-23p19 inhibitors, represent a class of targeted therapies with distinct pharmacokinetic and clinical profiles. While clinical trials have demonstrated efficacy in controlled environments, real-world data are imperative to understand performance across diverse populations. This study aims to compare the real-world effectiveness of Tremfaya and Tildrakizumab in patients with moderate-to-severe plaque psoriasis, focusing on long-term treatment response, safety, and drug survival over a 12-month period. The study analyzed anonymized patient records from multiple dermatology centers and used PASI (Psoriasis Area and Severity Index) reduction, Dermatology Life Quality Index (DLQI), and adverse event rates as outcome metrics. Findings reveal that Tremfaya achieved faster PASI 90 scores at week 16, while Tildrakizumab demonstrated slightly better long-term drug survival and tolerability. Both agents showed substantial improvement in DLQI. The study highlights nuanced differences in efficacy and supports personalized therapy selection in clinical practice.
Keywords
Plaque Psoriasis; Tremfaya; Tildrakizumab; IL-23 Inhibitors; Real-World Study; PASI Score; Biologic Therapy; Dermatology; Drug Survival; Comparative Effectiveness
References
- Langley RG, et al. “Guselkumab, an anti–interleukin-23 monoclonal antibody, for moderate-to-severe psoriasis.” NEJM, 2015; 373(14):1360–1369.
- Reich K, et al. “Tildrakizumab vs placebo and etanercept in moderate-to-severe psoriasis.” Lancet, 2017; 390(10091):276–288.
- Blauvelt A, et al. “Efficacy and safety of guselkumab in psoriasis: VOYAGE 1 and 2.” JAAD, 2017; 76(3):405–417.
- Thaci D, et al. “Impact of guselkumab on patient-reported outcomes: VOYAGE trials.” Br J Dermatol, 2017; 177(1):135–142.
- Papp KA, et al. “Safety of guselkumab in psoriasis patients: pooled VOYAGE data.” J Drugs Dermatol, 2017; 16(4):391–398.
- Lebwohl MG, et al. “Biologic therapies for psoriasis: IL-23 pathway insights.” J Am Acad Dermatol, 2016; 74(3):490–501.
- Leonardi C, et al. “Clinical trial evidence on tildrakizumab: reSURFACE 1 and 2.” J Eur Acad Dermatol Venereol, 2017; 31(3):409–417.
- Griffiths CEM, et al. “Comparison of biologics in psoriasis: beyond RCTs.” J Dermatol Treat, 2016; 27(6):511–518.
- Kircik L, et al. “IL-23 inhibitors in dermatologic practice: an overview.” Cutis, 2017; 99(1):13–16.
- Armstrong AW, et al. “Real-world data in psoriasis: strengths and limitations.” Dermatol Ther, 2017; 30(5):e12572.